NO951899L - Pyran-2-oner ig 5,6-dihydropyran-2-oner som kan anvendes for behandling av HIV og andre retrovirus - Google Patents

Pyran-2-oner ig 5,6-dihydropyran-2-oner som kan anvendes for behandling av HIV og andre retrovirus

Info

Publication number
NO951899L
NO951899L NO951899A NO951899A NO951899L NO 951899 L NO951899 L NO 951899L NO 951899 A NO951899 A NO 951899A NO 951899 A NO951899 A NO 951899A NO 951899 L NO951899 L NO 951899L
Authority
NO
Norway
Prior art keywords
ones
pyran
dihydropyran
retroviruses
treat hiv
Prior art date
Application number
NO951899A
Other languages
English (en)
Other versions
NO951899D0 (no
NO319914B1 (no
Inventor
Suvit Thaisrivongs
Chih-Ping Yang
Joseph Walter Strohbach
Steven Ronald Turner
Donna Lee Romero
Louis L Skaletzky
Paul Adrian Aristoff
Ronald B Gammill
Paul D Johnsen
Harvey Irving Skulnick
Richard C Piper
Ruben A Tommasi
Qingwei Zhang
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of NO951899D0 publication Critical patent/NO951899D0/no
Publication of NO951899L publication Critical patent/NO951899L/no
Publication of NO319914B1 publication Critical patent/NO319914B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
NO19951899A 1992-11-13 1995-05-12 Pyran-2-oner og 5,6-dihydropyran-2-oner, anvendelse derav til fremstilling av medikamenter som kan anvendes for behandling av HIV og inhibering av andre retrovirus, farmasoytiske preparater som omfatter forbindelsene, fremgangsmate for fremstilling av et pyran-2-on, samt forbindelse som er et mellomprodukt i fremgangsmaten. NO319914B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US97534392A 1992-11-13 1992-11-13
US9087693A 1993-07-13 1993-07-13
US13064193A 1993-10-01 1993-10-01
PCT/US1993/010645 WO1994011361A1 (en) 1992-11-13 1993-11-09 Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hiv and other retroviruses

Publications (3)

Publication Number Publication Date
NO951899D0 NO951899D0 (no) 1995-05-12
NO951899L true NO951899L (no) 1995-07-12
NO319914B1 NO319914B1 (no) 2005-10-03

Family

ID=27376682

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19951899A NO319914B1 (no) 1992-11-13 1995-05-12 Pyran-2-oner og 5,6-dihydropyran-2-oner, anvendelse derav til fremstilling av medikamenter som kan anvendes for behandling av HIV og inhibering av andre retrovirus, farmasoytiske preparater som omfatter forbindelsene, fremgangsmate for fremstilling av et pyran-2-on, samt forbindelse som er et mellomprodukt i fremgangsmaten.

Country Status (26)

Country Link
EP (2) EP1203770B1 (no)
JP (1) JP3583127B2 (no)
KR (1) KR100314975B1 (no)
CN (1) CN1040321C (no)
AT (2) ATE290531T1 (no)
AU (1) AU687368B2 (no)
BR (1) BR9307451A (no)
CA (1) CA2145661C (no)
CZ (1) CZ291853B6 (no)
DE (2) DE69332292T2 (no)
DK (2) DK0668860T3 (no)
ES (2) ES2237624T3 (no)
FI (1) FI120399B (no)
GE (1) GEP20094660B (no)
HU (1) HU228126B1 (no)
IL (1) IL107556A (no)
LV (1) LV13088B (no)
MY (1) MY119031A (no)
NO (1) NO319914B1 (no)
NZ (1) NZ258013A (no)
PL (1) PL178653B1 (no)
PT (2) PT668860E (no)
RU (1) RU2134691C1 (no)
SK (1) SK285001B6 (no)
WO (1) WO1994011361A1 (no)
ZA (1) ZA938019B (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0720607A1 (en) * 1993-09-17 1996-07-10 PHARMACIA & UPJOHN COMPANY Substituted tetronic acids useful for treating hiv and other retroviruses
FI962019A7 (fi) * 1993-11-19 1996-05-20 Parke Davis & Co Pyronijohdannaiset proteaasi-inhibiittoreina ja antiviraalisina ainein a
DE69433705T2 (de) * 1993-11-19 2005-03-10 Parke, Davis & Company 5,6-Dihydropyronderivate als Proteaseinhibitoren und Antiviralmittel
CA2176044A1 (en) * 1993-11-19 1995-05-26 Elizabeth Lunney Pyrone derivatives as protease inhibitors and antiviral agents
SK283240B6 (sk) * 1993-11-19 2003-04-01 Parke, Davis & Company 5,6-Dihydropyrónové deriváty ako inhibítory proteázy a protivírusové činidlá a farmaceutická kompozícia obsahujúca tieto deriváty
US6005103A (en) * 1993-11-19 1999-12-21 Warner-Lambert Company Pyrone derivatives as protease inhibitors and antiviral agents
US5789440A (en) * 1993-11-19 1998-08-04 Warner-Lambert Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
JPH11503416A (ja) * 1995-03-20 1999-03-26 ファルマシア・アンド・アップジョン・カンパニー Hivおよび他のレトロウイルス病を治療するのに有用な置換テトロン酸
WO1998000173A2 (en) * 1996-07-03 1998-01-08 Pharmacia & Upjohn Company Targeted drug delivery using sulfonamide derivatives
JP4462760B2 (ja) * 1997-09-11 2010-05-12 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー プロテアーゼインヒビターとして有用な4−ヒドロキシ−2−オキソ−ピラン誘導体の製法
WO1999046262A1 (en) 1998-03-12 1999-09-16 Teijin Limited Benzofurylpyrone derivatives
JP3929244B2 (ja) * 1998-12-25 2007-06-13 塩野義製薬株式会社 Hivインテグラーゼ阻害活性を有する芳香族ヘテロ環誘導体
FI113942B (fi) * 2000-08-18 2004-07-15 Control Ox Oy Kasviperäisten fenolisten yhdisteiden käyttö valmistettaessa klamydiainfektion hoidossa ja ennaltaehkäisyssä käyttökelpoista farmaseuttista valmistetta, terveyteen myönteisesti vaikuttavaa ravintoainekoostumusta tai koostumusta lisättäväksi tällaisiin elintarvikkeisiin
EP1281399A3 (en) * 2001-08-01 2004-02-11 Warner-Lambert Company Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production
DOP2003000641A (es) 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
RU2236852C1 (ru) * 2003-06-23 2004-09-27 Закрытое акционерное общество "ДЕСКО" Средство для ингибирования репродукции оболоченных вирусов, способ его получения, фармацевтическая композиция и способ ингибирования вирусных инфекций
CN101693664A (zh) 2003-10-24 2010-04-14 隆萨股份公司 6,6,6-三卤-3,5-二氧代己酸酯的制备方法
HRP20110845T1 (hr) * 2006-06-16 2011-12-31 Pharma Mar Antitumorski dihidropiran-2-onski spojevi
PT2231633E (pt) 2007-12-20 2014-01-20 Pharma Mar Sa Compostos antitumorais
DE102008055916A1 (de) 2008-11-05 2010-05-06 Clariant International Limited Verfahren zur Herstellung von mono-hydroxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Allylalkoholen und ihre Verwendung
DE102008055914A1 (de) 2008-11-05 2010-05-06 Clariant International Limited Verfahren zur Herstellung von mono-hydroxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Acroleinen und ihre Verwendung
WO2010051883A1 (de) 2008-11-05 2010-05-14 Clariant International Ltd Verfahren zur herstellung von dialkylphosphinsäuren, -estern und -salzen mittels allylalkoholen/acroleinen und ihre verwendung
DE102008056339A1 (de) 2008-11-07 2010-05-12 Clariant International Limited Verfahren zur Herstellung von mono-aminofunktionalisierten Dialkylphosphinsäuren, -estern und -salzen und ihre Verwendung
EP2352740B1 (de) 2008-11-07 2014-09-24 Clariant Finance (BVI) Limited Verfahren zur herstellung von dialkylphosphinsäuren, -estern und -salzen mittels acrylsäurederivaten und ihre verwendung
DE102008056341A1 (de) 2008-11-07 2010-05-12 Clariant International Limited Verfahren zur Herstellung von monoaminofunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Acrylnitrilen und ihre Verwendung
DE102008056342A1 (de) 2008-11-07 2010-05-12 Clariant International Limited Verfahren zur Herstellung von Dialkylphosphinsäuren, -estern und -salzen mittels Acrylnitrilen und ihre Verwendung
EP2367835B1 (de) 2008-11-11 2013-12-11 Clariant Finance (BVI) Limited Verfahren zur herstellung von mono-allylfunktionalisierten dialkylphosphinsäuren, deren salze und ester mit allylischen verbindungen und ihre verwendung
DE102008060036A1 (de) * 2008-12-02 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-carboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylester einer Carbonsäure und ihre Verwendung
DE102008060035A1 (de) 2008-12-02 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-hydroxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylester einer Carbonsäure und ihre Verwendung
DE102008060535A1 (de) * 2008-12-04 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-carboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylether und ihre Verwendung
KR101697948B1 (ko) 2008-12-18 2017-01-19 클라리언트 파이넌스 (비브이아이)리미티드 아세틸렌을 사용하는 에틸렌디알킬포스핀산, 에틸렌디알킬포스핀산 에스테르 및 에틸렌디알킬포스핀산 염의 제조방법 및 이의 용도
DE102008063627A1 (de) 2008-12-18 2010-06-24 Clariant International Limited Verfahren zur Herstellung von monohydroxyfunktionalisierten Dialkylphosphinsäuren,-estern und -salzen mittels Ethylenoxid und ihre Verwendung
DE102008063642A1 (de) * 2008-12-18 2010-06-24 Clariant International Limited Verfahren zur Herstellung von monocarboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Alkylenoxiden und ihre Verwendung
DE102008063668A1 (de) 2008-12-18 2010-07-01 Clariant International Limited Verfahren zur Herstellung von Alkylphosponsäuren, -estern und -salzen mittels Oxidation von Alkylphosphonigsäuren und ihre Verwendung
DE102008064012A1 (de) 2008-12-19 2010-06-24 Clariant International Limited Halogenfreie Addukte von Alkylphosphonigsäurederivaten und diesterbildenden Olefinen, halogenfreie Verfahren zu deren Herstellung und ihre Verwendung
DE102008064003A1 (de) 2008-12-19 2010-06-24 Clariant International Limited Verfahren zur Herstellung von mono-funktionalisierten Dialkylphosphinsäuren, -estern und -salzen und ihre Verwendung
US20120202814A1 (en) * 2009-10-02 2012-08-09 Università Degli Studi Di Siena Compounds with ddx3 inhibitory activity and uses thereof
CN102690275A (zh) * 2011-03-25 2012-09-26 中国人民解放军第二军医大学 四氢呋喃并[3,4-c]吡喃酮类化合物及其制备方法和用途
CN103044375B (zh) * 2012-12-02 2015-08-12 大理学院 一种二氢吡喃酮化合物及其制备方法和药物用途
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
CN114835694B (zh) * 2022-05-25 2024-06-21 中国科学技术大学 一种在水介质中合成手性3,4-二氢-2h-吡喃类化合物的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1276654A (fr) * 1958-10-01 1961-11-24 Nouveaux dérivés de l'hydroxy-4-alpha-2-pyrone
FR1276645A (fr) * 1959-12-28 1961-11-17 Wild Heerbrugg Ag Objectif de microscope
ZA883034B (en) * 1987-04-29 1989-03-29 Smithkline Beckman Corp Steroid 5-alpha-reductase inhibitors
WO1989007939A2 (en) * 1988-03-01 1989-09-08 The Upjohn Company Coumarins to inhibit reverse transcriptase in humans
WO1991004663A1 (en) * 1989-09-26 1991-04-18 The Regents Of The University Of California 6-amino-1,2-benzopyrones useful for treatment of viral diseases
WO1991006561A1 (en) * 1989-10-27 1991-05-16 The Upjohn Company Method for treating hiv and other retroviruses and compounds useful therefor
DE4103904C2 (de) * 1991-02-08 1995-06-14 Analyticon Ges Fuer Chemische Neue Arzneimittel aus Gamma-Pyronen, Gamma-Pyridonen sowie Gamma-Thiopyronen

Also Published As

Publication number Publication date
CA2145661C (en) 2008-04-01
PL178653B1 (pl) 2000-05-31
BR9307451A (pt) 1999-08-31
CN1040321C (zh) 1998-10-21
DK1203770T3 (da) 2005-05-23
PL308998A1 (en) 1995-09-18
RU95112465A (ru) 1997-03-20
FI952302A0 (fi) 1995-05-11
DE69332292T2 (de) 2003-05-28
ZA938019B (en) 1995-04-28
KR100314975B1 (ko) 2002-02-28
SK285001B6 (sk) 2006-04-06
HU228126B1 (en) 2012-12-28
EP0668860B1 (en) 2002-09-11
RU2134691C1 (ru) 1999-08-20
EP1203770B1 (en) 2005-03-09
CZ107895A3 (en) 1995-12-13
IL107556A0 (en) 1994-02-27
PT668860E (pt) 2003-01-31
CA2145661A1 (en) 1994-05-26
JPH08503216A (ja) 1996-04-09
MY119031A (en) 2005-03-31
JP3583127B2 (ja) 2004-10-27
NO951899D0 (no) 1995-05-12
HUT71558A (en) 1995-12-28
CN1090279A (zh) 1994-08-03
DK0668860T3 (da) 2003-01-20
EP1203770A1 (en) 2002-05-08
IL107556A (en) 2001-08-08
NZ258013A (en) 1997-02-24
CZ291853B6 (cs) 2003-06-18
GEP20094660B (en) 2009-03-25
LV13088B (en) 2004-01-20
DE69333771T2 (de) 2006-04-06
WO1994011361A1 (en) 1994-05-26
ATE223910T1 (de) 2002-09-15
ES2182837T3 (es) 2003-03-16
FI952302L (fi) 1995-05-11
DE69333771D1 (de) 2005-04-14
SK61695A3 (en) 1995-10-11
DE69332292D1 (de) 2002-10-17
HU9501411D0 (en) 1995-06-28
AU5549394A (en) 1994-06-08
NO319914B1 (no) 2005-10-03
ES2237624T3 (es) 2005-08-01
PT1203770E (pt) 2005-05-31
AU687368B2 (en) 1998-02-26
FI120399B (fi) 2009-10-15
ATE290531T1 (de) 2005-03-15
EP0668860A1 (en) 1995-08-30
KR950704290A (ko) 1995-11-17

Similar Documents

Publication Publication Date Title
NO951899D0 (no) Pyran-2-oner ig 5,6-dihydropyran-2-oner som kan anvendes for behandling av HIV og andre retrovirus
NO961575D0 (no) 16-substituerte-4-aza-androstan 5 hibitorer
NO20002409L (no) FremgangsmÕte for Õ produsere arsen trioksyd formuleringer og metoder for Õ behandle cancer ved Õ bruke arsen trioksyd eller melarsoprol
TR199801195T2 (xx) Tedavide yararl� kinolin ve kinozilin bile�ikleri.
MY138240A (en) Method of treating androgenic alopecia with 5- alpha reductase inhibitors.
LV12103A (lv) 5-alfa-reduktazes inhibitora pielietojums androgenas alopecijas arstesanai
FI931765A7 (fi) Steroidijohdannaisia eturauhasen liikakasvun käsittelyyn, niiden valmistus ja käytöt
ATE178795T1 (de) 7-substituierte-4-aza-steroid-derivate als 5- alpha-reductase-hemmer
EP0641208A4 (en) 4-AZASTEROIDS AS 5-ALPHA REDUCTASE.
HU9501286D0 (en) Methods and compositions of (+) doxazosin for the treatment of benign prostatic hyperplasia and atherosclerosis
LV12721A (lv) 17-beta-carboxanilides of 4-aza-5-alpha-androstan-3-ones as 5-alpha-reductase inhibitors
ATE198274T1 (de) 17 beta-aryl-4-aza-steroidderivate
IT1251772B (it) Processo per l'ossidazione di materiali organici con perossido di idrogeno in condizioni di irraggiamento in fase acquosa
MY108848A (en) Compositions and method of treating depigmentation disorders.
KR950700746A (ko) 양성 전립선 비대를 치료하는 조성물 및 방법(Compositions and Methods For Treating Benign Prostatic Hypertrophy)
GR851409B (no)
BR9203266A (pt) Composto,formulacao farmaceutica,processo para inibir 5alfa-reductase,processos para tratar hiperplasia benigna da prostata,seborreia e alopecia androgenica
AU5457694A (en) Methods and compositions of (-) doxazosin for the treatment of benign prostatic hyperplasia and atherosclerosis
NO975838L (no) Melatoninagonister for behandling av godartet prostatisk hyperplasi
HK1012275A (en) Compositions and methods for treating benign prostatic hypertrophy
AU6374798A (en) Methods and compositions of (+) doxazosin for the treatment of hypertension and benign prostatic hyperplasia
UA34374A (uk) Спосіб лікування виразкової хвороби дванадцятипалої кишки

Legal Events

Date Code Title Description
MK1K Patent expired